Molecular Pathology Laboratory Management

Rennert, Hanna; Leonard, Debra G.B.

doi:10.1007/978-0-387-33227-7_49

Cited by 1 publication

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For any procedures that require PCR, carryover of amplicons between samples is a significant issue. 155 Techniques that can be performed in a single, closed tube (e.g., such as qPCR) are therefore at a significant advantage compared to assays that require post-PCR sample manipulation. Tests should ideally be designed to incorporate quality control, including internal controls for DNA input quantity and reaction success.…”

Section: ■ Advanced Detection Systemsmentioning

confidence: 99%

“…Methods that require specialist equipment will need to be widely adaptable to ensure that investment is worthwhile, whereas methods that utilize equipment that is already common have a natural advantage. For any procedures that require PCR, carryover of amplicons between samples is a significant issue . Techniques that can be performed in a single, closed tube (e.g., such as qPCR) are therefore at a significant advantage compared to assays that require post-PCR sample manipulation.…”

Section: Insightsmentioning

confidence: 99%

See 1 more Smart Citation

Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations: Techniques and Challenges

Rodda¹,

Parker

Spencer

et al. 2018

ACS Sens.

View full text Add to dashboard Cite

Liquid biopsies that analyze circulating tumor DNA (ctDNA) hold great promise in the guidance of clinical treatment for various cancers. However, the innate characteristics of ctDNA make it a difficult target: ctDNA is highly fragmented, and found at very low concentrations, both in absolute terms and relative to wildtype species. Clinically relevant target sequences often differ from the wildtype species by a single DNA base pair. These characteristics make analyzing mutant ctDNA a uniquely difficult process. Despite this, techniques have recently emerged for analyzing ctDNA, and have been used in pilot studies that showed promising results. These techniques each have various drawbacks, either in their analytical capabilities or in practical considerations, which restrict their application to many clinical situations. Many of the most promising potential applications of ctDNA require assay characteristics that are not currently available, and new techniques with these properties could have benefits in companion diagnostics, monitoring response to treatment and early detection. Here we review the current state of the art in ctDNA detection, with critical comparison of the analytical techniques themselves. We also examine the improvements required to expand ctDNA diagnostics to more advanced applications and discuss the most likely pathways for these improvements.

show abstract

Section: ■ Advanced Detection Systemsmentioning

confidence: 99%

Section: Insightsmentioning

confidence: 99%